RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19 Print E-mail
GlobeNewswire
Thursday, 30 July 2020 02:00

The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy, Brazil and Mexico

Read more...
 
Adventist Health Tulare Turns to Mach7’s eUnity SMARTviewer and Universal Worklist to Power its Radiology Reading Strategy Print E-mail
GlobeNewswire
Thursday, 30 July 2020 02:00

BURLINGTON, Vt., July 30, 2020 (GLOBE NEWSWIRE)

Read more...
 
Lifted Made Launches Flavored Nano CBD Water Enhancer Packets Under its Urb Finest Flowers Brand Print E-mail
GlobeNewswire
Thursday, 30 July 2020 02:00

ZION, Il, July 30, 2020 (GLOBE NEWSWIRE)

Read more...
 
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia Print E-mail
GlobeNewswire
Thursday, 30 July 2020 02:00

BOSTON, July 30, 2020 (GLOBE NEWSWIRE)

Read more...
 
Teleflex Reports Second Quarter 2020 Results Print E-mail
GlobeNewswire
Thursday, 30 July 2020 01:30

Second Quarter Revenues of $567.0 million, down 13.1% versus Prior Year Period; down 12.0% on a Constant Currency Basis

Second Quarter GAAP Diluted EPS from Continuing Operations of $0.24, Compared to $1.77 in the Prior Year Period

Second Quarter Adjusted Diluted EPS from Continuing Operations of $1.93, down 27.4% Versus Prior Year Period

New Workforce Reduction Plan to Further Improve Company Cost Structure Announced

 Not Reinstating 2020 Financial Guidance due to COVID-19 Pandemic

WAYNE, Pa., July 30, 2020 (GLOBE NEWSWIRE)

Read more...
 
Teleflex Announces 200,000 Patients Treated with UroLift System for Enlarged Prostate Print E-mail
GlobeNewswire
Thursday, 30 July 2020 01:00

WAYNE, Pa., July 30, 2020 (GLOBE NEWSWIRE)

Read more...
 
An executive coach intertwines personal stories with soulful life lessons to help others create a brighter future Print E-mail
GlobeNewswire
Wednesday, 29 July 2020 19:00

SANTA ANA, Calif., July 30, 2020 (GLOBE NEWSWIRE)

Read more...
 
CytoDyn Completes Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share without Warrants Print E-mail
GlobeNewswire
Wednesday, 29 July 2020 13:56

VANCOUVER, Washington, July 29, 2020 (GLOBE NEWSWIRE)

Read more...
 
Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT Print E-mail
GlobeNewswire
Wednesday, 29 July 2020 11:30

NEW YORK, July 29, 2020 (GLOBE NEWSWIRE)

Read more...
 
Inovalon Reports Second Quarter 2020 Results Print E-mail
GlobeNewswire
Wednesday, 29 July 2020 11:10

Second Quarter 2020 Highlights

  • Q2 revenue of $162.2 million, up 3% YoY
  • Q2 subscription-based platform revenue of $142.1 million, up 13% YoY, equating to 88% of Q2 total revenue
  • Q2 net income of $2.0 million, resulting in diluted net income of $0.01 per share
  • Q2 Non-GAAP net income of $22.0 million, up 15% YoY, resulting in Non-GAAP net income of $0.15 per share
  • Q2 Adjusted EBITDA of $56.6 million, up 8% YoY, resulting in Adjusted EBITDA margin of 34.9%
  • Q2 net cash provided by operating activities of $49.0 million
  • Q2 new sales Annual Contract Value (ACV)1 totaled a record $75.7 million, up 38.1% YoY

Debt & Cash Highlights

  • Voluntarily repaid $99 million (100% of all outstanding amounts) of revolver on June 4, 2020
  • Cash balance as of June 30, 2020 totaling $95.6 million
  • Net debt leverage ratio as of June 30, 2020 improved to 3.69x (versus 4.32x on June 30, 2019)

Trailing Twelve Month (TTM)2 Second Quarter 2020 Highlights

  • TTM Q2 revenue of $656.3 million, up 12% period-over-period
  • TTM Q2 subscription-based platform revenue of $563.1 million up 17% period-over-period, equating to 86% of period revenue
  • TTM Q2 net income of $11.9 million
  • TTM Q2 Non-GAAP net income of $81.9 million, up 42% period-over-period
  • TTM Q2 Adjusted EBITDA of $218.0 million, up 16% period-over-period
  • TTM Q2 net cash provided by operating activities of $129.7 million
  • TTM Q2 new sales ACV totaled $238.7 million

2020 Guidance Highlights

  • Raising low end of revenue range, and increasing Adjusted EBITDA and Non-GAAP diluted earnings per share guidance for full year 2020
  • Providing third quarter 2020 guidance

Please refer to our Second Quarter 2020 Earnings Presentation Supplement available at http://investors.inovalon.com for additional information, 2020 financial guidance, additional financial metrics, and other topics that will be referenced during the Company’s conference call.

BOWIE, Md. , July 29, 2020 (GLOBE NEWSWIRE)

Read more...
 
UPDATE – UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results Print E-mail
GlobeNewswire
Wednesday, 29 July 2020 11:05

SAN FRANCISCO, July 29, 2020 (GLOBE NEWSWIRE)

Read more...
 
Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis Print E-mail
GlobeNewswire
Wednesday, 29 July 2020 08:30

NEWTOWN, Pa., July 29, 2020 (GLOBE NEWSWIRE)

Read more...
 
Medical Laser Market to Exhibit CAGR of 13.9% by 2027; Accountable to Rising Prevalence of Coronary Artery Diseases: Fortune Business Insights™ Print E-mail
GlobeNewswire
Wednesday, 29 July 2020 07:21

Pune, July 29, 2020 (GLOBE NEWSWIRE)

Read more...
 
KOELIS Announces Partnership with GMP, Providing VA Hospitals with Access to Advanced Prostate Care Technology Print E-mail
GlobeNewswire
Wednesday, 29 July 2020 07:01

PRINCETON, N.J., July 29, 2020 (GLOBE NEWSWIRE)

Read more...
 
Telehealth Market to Exhibit 25.2% CAGR till 2027; Rising Preference for E-visits Owing to Their Cost-effectiveness will Boost Growth: Fortune Business Insights™ Print E-mail
GlobeNewswire
Wednesday, 29 July 2020 05:31

Pune, July 29, 2020 (GLOBE NEWSWIRE)

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 6 of 281

Newsletter